The figures, for anyone assembling their own picture. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.
Following on from Dr.LeslieOBGYN — and this may be the naive question:
How often to repeat it, because quarterly seems to be the convention and I cannot find the reasoning?
FDA_TrackerJim said:With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…
There is a second half to this that has not been said yet. The liver data is among the strongest non-weight findings in the class. The semaglutide MASH programme reported a large advantage over placebo on MASH resolution, with a substantial minority also achieving fibrosis improvement — and fibrosis is the endpoint that predicts outcomes. Mechanistically it is reduced hepatic lipogenesis, increased fatty-acid oxidation, less hepatic inflammation, and possibly a direct effect on stellate-cell activation.
Ask again with the specifics and you will get a better answer than this one.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsClosing the loop on my own question.
Took the whole panel in rather than the one flagged line, and the conversation lasted two minutes instead of generating three more tests.
Dr.KarenChen said:The liver data is among the strongest non-weight findings in the class.
Dr.KarenChen has the substance of this right. The condition it depends on is worth stating. One addition: if the lab changes analytical platform between your draws, the comparison breaks and nobody tells you. It is worth asking when a value moves inexplicably.